Products resulting from cleavage of the interglobular domain of aggrecan in samples of synovial fluid collected from dogs with early- and late-stage osteoarthritis

American Journal of Veterinary Research

Volumn 66, Issue 10, 2005, Pages 1679-1685

  Innes, John F ^a   Little, Chris B ^b,c   Hughes, Clare E ^b   Caterson, Bruce ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; AGGRECANASE; BIOLOGICAL MARKER; EPITOPE; GLYCOSAMINOGLYCAN; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; PROTEOGLYCAN;

ARTICLE; ARTICULAR CARTILAGE; BIOASSAY; CONTROLLED STUDY; DOG DISEASE; ELBOW; HINDLIMB; MOLECULAR WEIGHT; NONHUMAN; OSTEOARTHRITIS; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; SAMPLING; SYNOVIAL FLUID; WESTERN BLOTTING;

AGGRECANS; ANIMALS; BLOTTING, WESTERN; DOG DISEASES; DOGS; ENDOPEPTIDASES; EXTRACELLULAR MATRIX PROTEINS; GLYCOSAMINOGLYCANS; LECTINS, C-TYPE; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; PROTEIN STRUCTURE, TERTIARY; PROTEOCHONDROITIN SULFATES; SYNOVIAL FLUID;

CANIS FAMILIARIS;

EID: 27844543298     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.1679     Document Type: Article

References (34)

1. Boulay JP. Fragmented medial coronoid process of the ulna in the dog. Vet Clin North Am Small Anim Pract 1998;28:51-76.
2. Innes JF, Barr ARS, Clinical natural history of the post surgical cruciate deficient canine stifle joint: year one. J Small Anim Pract 1998;39:325-332.
3. van Ryssen B, van Bree H. Arthroscopic findings in 100 dogs with elbow lameness. Vet Rec 1997;140:360-362.
4. Huibregtse BA, Johnson AL, Muhlbauer MC, et al. The effect of treatment of fragmented coronoid process on the development of osteoarthritis of the elbow. J Am Anim Hosp Assoc 1994;30:190-195.
5. Pond M, Nuki G. Experimentally induced osteoarthritis in the dog. Ann Rheum Dis 1973;32:387-388.
6. Brandt KD, Braunstein EM, Visco DM, et al. Anterior (cranial) cruciate ligament transection in the dog - a bona-fide model of osteoarthritis, not merely of cartilage injury and repair. J Rheumatol 1991;18:436-446.
7. Brandt KD, Myers SL, Burr D, et al. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum 1991;34:1560-1570.
8. Ratcliffe A, Billingham ME, Saed NF, et al. Increased release of matrix components from articular cartilage in experimental canine osteoarthritis. J Orthop Res 1992;10:350-358.
9. Poole AR. Proteoglycans in health and disease: structures and functions. Biochem J 1986;236:1-14.
10. Mow VC, Ratcliffe A, Poole AR. Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures. Biomaterials 1992;13:67-97.
11. Hardingham TE, Fosang AJ. The structure of aggrecan and its turnover in cartilage. J Rheumatol 1995;22:86-90.
12. Abbaszade I, Liu RQ, Yang F, et al. Cloning and characterization of ADAMTSII, an aggrecanase from the ADAMTS family. J Biol Chem 1999;274:23443-23450.
13. Tortorefla MD, Burn TC, Pratta MA, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999;284:1664-1666.
14. Lohmander L, Hoerrner L, Dahlberg L, et al. Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury. J Rheumatol 1993;20:1362-1368.
15. Lark MW, Bayne EK, Flanagan J, et al. Aggrecan degradation in human cartilage - evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997;100:93-106.
16. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis - evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996;98:2292-2299.
17. Arner EC, Hughes CE, Decicco CP, et al. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis Cartilage 1998;6:214-228.
18. Little CB, Flannery CR, Hughes CE, et al. Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J 1999;344:61-68.
19. Hughes CE, Caterson B, Fosang AJ, et al. Monoclonal antibodies that specifically recognise neoepitope sequences generated by aggrecanase and matrix metalloproteinase cleavage of aggrecan - application to catabolism in situ and in vitro. Biochem J 1995;305:799-804.
20. Caterson B, Flannery CR, Hughes CE, et al. Mechanisms of proteoglycan metabolism that lead to cartilage destruction in the pathogenesis of arthritis. Drugs Today (Barc) 1999;35:397-402.
21. Sandy JD, Verscharen C. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J 2001;358:615-626.
22. Little CB, Hughes CE, Curtis CL, et al. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol 2002;21:271-288.
23. van Meurs JBJ, van Lent P, Holthuysen AEM, et al. Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum 1999;42:1128-1139.
24. van Meurs JBJ, van Lent P, Singer II, et al. Interleukin-1 receptor antagonist prevents expression of the metalloproteinase-generated neoepitope VDIPEN in antigen-induced arthritis. Arthritis Rheum 1998;41:647-656.
25. Innes JF, Sharif M, Barr ARS. Changes in concentrations of biochemical markers of osteoarthritis following surgical repair of ruptured cranial cruciate ligaments in dogs. Am J Vet Res 1999;60:1164-1168.
26. Innes J, Sharif M, Barr A. Relations between biochemical markers of osteoarthritis and other disease parameters in a population of dogs with naturally acquired osteoarthritis of the genual joint. Am J Vet Res 1998;59:1530-1536.
27. Farndale RW, Buttle DJ, Barrett AJ. Improved quantification and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986;883:173-177.
28. Hughes CE, Little CB, Buttner FH, et al. Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J Biol Chem 1998;273:30576-30582.
29. Caterson B, Hughes CE, Roughley P, et al. Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis. Acta Orthop Scand 1995;66:121-124.
30. Christner JE, Caterson B, Baker JR. Immunological determinants of proteoglycans. Antibodies against the unsaturated oligosaccharide products of chondroitinase ABC-digested cartilage proteoglycans. J Biol Chem 1980;255:7102-7105.
31. Ratcliffe A, Shurety W, Caterson B. The quantitation of native chondroitin sulfate epitope in synovial fluid lavages and articular cartilage from canine experimental osteoarthritis and disuse atrophy. Arthritis Rheum 1993;36:543-551.
32. Inkinen RI, Lammi MJ, Lehmonen S, et al. Relative increase of biglycan and decorin and altered chondroitin sulfate epitopes in the degenerating human intervertebral disc. J Rheumatol 1998;25:506-514.
33. Sztrolovics R, Alini M, Roughley PJ, et al. Aggrecan degradation in human intervertebral disc and articular cartilage. Biochem J 1997;326:235-241.
34. Rees SG, Flannery CR, Little CB, et al. Catabolism of aggrecan, decorin and biglycan in tendon. Biochem J 2000; 350:181-188.